Allianz Asset Management GmbH Acquires 71,548 Shares of Insulet Corporation $PODD

Allianz Asset Management GmbH boosted its holdings in Insulet Corporation (NASDAQ:PODD) by 27.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 334,426 shares of the medical instruments supplier’s stock after purchasing an additional 71,548 shares during the quarter. Allianz Asset Management GmbH owned 0.48% of Insulet worth $103,247,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in PODD. Peak Retirement Planning Inc. raised its position in shares of Insulet by 39.1% in the third quarter. Peak Retirement Planning Inc. now owns 6,380 shares of the medical instruments supplier’s stock valued at $1,970,000 after buying an additional 1,795 shares in the last quarter. Atlantic Union Bankshares Corp increased its stake in Insulet by 738.7% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 629 shares of the medical instruments supplier’s stock worth $194,000 after acquiring an additional 554 shares during the period. Bridges Investment Management Inc. raised its holdings in Insulet by 20.8% in the 3rd quarter. Bridges Investment Management Inc. now owns 802 shares of the medical instruments supplier’s stock valued at $248,000 after acquiring an additional 138 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Insulet by 3.6% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,789 shares of the medical instruments supplier’s stock valued at $569,000 after acquiring an additional 62 shares in the last quarter. Finally, A4 Wealth Advisors LLC bought a new stake in shares of Insulet during the 3rd quarter valued at $222,000.

Insulet Trading Down 2.1%

Shares of PODD stock opened at $251.22 on Wednesday. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $354.88. The stock’s fifty day simple moving average is $288.38 and its 200 day simple moving average is $308.85. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $17.67 billion, a P/E ratio of 72.82, a P/E/G ratio of 1.45 and a beta of 1.41.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The firm had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same period last year, the firm posted $1.08 earnings per share. The business’s revenue for the quarter was up 29.9% on a year-over-year basis. As a group, sell-side analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

PODD has been the subject of a number of analyst reports. Jefferies Financial Group boosted their price target on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Truist Financial cut their price target on shares of Insulet from $412.00 to $390.00 and set a “buy” rating for the company in a report on Thursday, December 18th. The Goldman Sachs Group reiterated a “buy” rating and set a $365.00 price target on shares of Insulet in a research report on Friday, January 9th. BTIG Research lifted their price objective on shares of Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a research note on Friday, November 21st. Finally, Zacks Research cut Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Twenty analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $375.05.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.